Eli Lilly acquires three vaccine firms for up to $3.83 billion, including GC Biopharma affiliate

Global pharmaceutical giant Eli Lilly is significantly expanding its footprint in infectious disease prevention with the acquisition of three vaccine companies, including Curagen, a US-based affiliate co-invested in by South Korea's GC Biopharma. The move signals a strategic shift to bolster its vaccine pipeline, building on the substantial revenue generated from its blockbuster GLP-1 drugs for obesity and diabetes.

“

Eli Lilly is acquiring three vaccine companies, including Curagen, LimmaTech Biologics, and Vaccine Company, with a total transaction value of up to $3.83 billion.

The total value of the deals could reach up to $3.83 billion (approximately 5 trillion Korean won). This acquisition spree follows Lilly's recent recruitment of Dr. Peter Marks, former director of the FDA's Center for Biologics Evaluation and Research (CBER), to lead its infectious disease division, underscoring the company's commitment to this new area of focus.

Curagen, which Lilly is acquiring for up to $1.5 billion, is developing a next-generation shingles vaccine candidate called AmezoSvatein. This vaccine aims to improve upon existing treatments by reducing side effects like fatigue and pain while maintaining efficacy. The shingles vaccine market is currently dominated by GSK's Shingrix, but AmezoSvatein's focus on better tolerability could offer a competitive advantage, especially as research increasingly links shingles to other health issues like stroke and dementia.

“

Curagen was co-invested in by GC Biopharma with US-based experts in November 2017 with the goal of entering the global vaccine market.

Lilly is also acquiring LimmaTech Biologics for up to $780 million, which is developing vaccines against bacterial pathogens like Staphylococcus aureus and Neisseria gonorrhoeae, addressing the growing threat of antibiotic resistance. The third acquisition is Vaccine Company for up to $1.55 billion, focusing on viral vaccines using its proprietary nanoparticle technology, with a lead candidate targeting the Epstein-Barr virus (EBV).

“

AmezoSvatein focuses on improving the tolerability of existing shingles vaccines by reducing side effects like fatigue and pain.

Industry observers view these acquisitions as Eli Lilly's strategic deployment of capital generated from its highly successful GLP-1 medications into new growth areas. By diversifying into vaccines, Lilly is not only seeking short-term revenue but also investing in long-term pipeline value and addressing global public health needs, particularly in light of increasing antibiotic resistance.

“

LimmaTech is developing vaccines against bacterial pathogens such as Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis.